Skip to main content
Equibles
GLSI logo

GLSI · Greenwich LifeSciences, Inc. · Metrics

Track GLSI — free

Use GLSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.28 -0.81 (-5.03%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$224.28M
Shares
14.68M
Volume · Nov 12 207.01K Avg daily vol (3M) 129.33K

GLSI metrics

65 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.28
Market cap
$224.28M

Price action

23 metrics
Price change (1W)
-1.6%
Price change (30D)
+3.8%
Price change (3M)
-4.9%
Price change (6M)
-36.4%
Price change (YTD)
-23.4%
Price change (1Y)
+90.0%
Trailing year
Price change (5Y)
-55.4%
52-week high
$33.57
52-week low
$7.85
Change from 52-week high
-52.1%
Change from 52-week low
+105.0%
Annualized volatility
106.0%
Annualized volatility (3M)
92.8%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
3.3
RSI (14D)
48.4
Price vs SMA 50
-3.0%
Price vs SMA 200
-23.9%
Avg volume (3M)
129,225
Relative volume
0.9
Average dollar volume
$2.15M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
14.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
75.8
reciprocal yield 1.3%
FCF yield
—
TTM · current market cap
Buyback yield
3.2%
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$22.66M
Net income (TTM)
−$22.47M
Trailing 12 months
Diluted EPS (TTM)
$-1.60
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.60
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.59
Operating cash flow per diluted share (TTM)
$-0.88
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.43
Stock compensation per diluted share (TTM)
$0.48
Book value per share
$0.02

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-720.9%
Return on assets
-253.2%
Debt / equity
0.0
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$8.88M
Latest balance sheet
Cash & equivalents
$8.88M
Total assets
$8.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.49M
Capital expenditures (TTM)
—
R&D (TTM)
$20.30M
SG&A (TTM)
—
Stock compensation (TTM)
$6.74M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
59
13F filer change QoQ
-7
Institutional ownership
11.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.5%
Private-fund adviser ownership
0.3%
Active holders' share change QoQ
-3.5%
Holder tenure
9.4
Price vs estimated holder cost
+22.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.3%

Short interest

3 metrics
Short interest
10.8%
Latest settlement · 12.5 days to cover
Days to cover
12.5d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1799788 CUSIP 396879108 13F (30d) 56 filings 30 filers Visit website Investor relations